These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9012634)

  • 21. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting.
    Böttiger C; Koch W; Lahn C; Mehilli J; von Beckerath N; Schömig A; Kastrati A
    Am Heart J; 2003 Nov; 146(5):855-61. PubMed ID: 14597935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.
    Zhan M; Zhou Y; Han ZC
    Int J Hematol; 2004 May; 79(4):400-4. PubMed ID: 15218974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
    van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
    Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.
    Rallidis LS; Gialeraki A; Merkouri E; Liakos G; Dagres N; Sionis D; Travlou A; Lekakis J; Kremastinos DT
    J Thromb Thrombolysis; 2010 May; 29(4):497-502. PubMed ID: 19844663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
    Hermans PW; Hibberd ML; Booy R; Daramola O; Hazelzet JA; de Groot R; Levin M
    Lancet; 1999 Aug; 354(9178):556-60. PubMed ID: 10470700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke.
    Boncoraglio GB; Bodini A; Brambilla C; Carriero MR; Ciusani E; Parati EA
    Cerebrovasc Dis; 2006; 22(2-3):191-5. PubMed ID: 16735791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome].
    Reshetniak TM; Ostriakova EV; Patrusheva NL; Patrushev LI; Aleksandrova EN; Seredavkina NV; Volkov AV; Nasonov EL
    Ter Arkh; 2013; 85(1):76-84. PubMed ID: 23536951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis.
    Nikolopoulos GK; Bagos PG; Tsangaris I; Tsiara CG; Kopterides P; Vaiopoulos A; Kapsimali V; Bonovas S; Tsantes AE
    Clin Chem Lab Med; 2014 Jul; 52(7):937-50. PubMed ID: 24695040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
    Lin S; Huiya Z; Bo L; Wei W; Yongmei G
    Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.
    Jeng JR
    Am J Hypertens; 2003 Apr; 16(4):290-6. PubMed ID: 12670745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
    Burzotta F; Iacoviello L; Di Castelnuovo A; Zamparelli R; D'Orazio A; Amore C; Schiavello R; Donati MB; Maseri A; Possati G; Andreotti F
    J Thromb Thrombolysis; 2003 Dec; 16(3):149-54. PubMed ID: 15087600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
    Seguí R; Estellés A; Mira Y; España F; Villa P; Falcó C; Vayá A; Grancha S; Ferrando F; Aznar J
    Br J Haematol; 2000 Oct; 111(1):122-8. PubMed ID: 11091191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction.
    Doggen CJ; Bertina RM; Cats VM; Reitsma PH; Rosendaal FR
    Thromb Haemost; 1999 Jul; 82(1):115-20. PubMed ID: 10456464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.
    Anvari A; Schuster E; Gottsauner-Wolf M; Wojta J; Huber K
    Thromb Res; 2001 Jul; 103(2):103-7. PubMed ID: 11457467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction.
    Parpugga TK; Tatarunas V; Skipskis V; Kupstyte N; Zaliaduonyte-Peksiene D; Lesauskaite V
    Dis Markers; 2015; 2015():260101. PubMed ID: 26273123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.
    Grubic N; Stegnar M; Peternel P; Kaider A; Binder BR
    Thromb Res; 1996 Dec; 84(6):431-43. PubMed ID: 8987164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.